Appili Therapeutics (APLIF) Stock Price, News & Analysis

Company Overview

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.

Key Stats

• Today's Range: $0.02 to $0.02
• 50-Day Range: $0.02 to $0.03
• 52-Week Range: $0.01 to $0.04
• Volume: 10,000 shs
• Average Volume: 81,213 shs
• Market Capitalization: $2.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

APLIF Stock Analysis - Frequently Asked Questions

How have APLIF shares performed this year?

Appili Therapeutics' stock was trading at $0.0280 at the start of the year. Since then, APLIF stock has decreased by 25.7% and is now trading at $0.0208.
View the best growth stocks for 2025 here.

How were Appili Therapeutics' earnings last quarter?

Appili Therapeutics Inc. (OTCMKTS:APLIF) released its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.01) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.01).

How do I buy shares of Appili Therapeutics?

Shares of APLIF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/13/2024
• Today: 5/13/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:APLIF
• CIK: N/A
• Web: www.appilitherapeutics.com
• Phone: 902-442-4655
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-2,800,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -209.09%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.11
• Quick Ratio: 0.11

Sales & Book Value

• Annual Sales: $630,000.00
• Price / Sales: 4.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.05) per share
• Price / Book: -0.42

Miscellaneous

• Outstanding Shares: 121,266,000
• Free Float: 106,908,000
• Market Cap: $2.52 million
• Optionable: Not Optionable
• Beta: -0.51